StreetInsider.com News Articles

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko brings more than two decades of experience in biotechnology finance, strategy, and capital markets. She most recently served as Managing Director and Senior Biotechnology Analyst at Evercore ISI, covering small- and mid-cap biotechnology companies. Prior to that role, she was a senior biotechnology analyst at JMP Securities and held positions in biopharma equity research at Next Generation Equity Research, Prudential Equity Group, and Baker Brothers Advisors. She began her career in corporate strategy at Searle/Pharmacia.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Therapeutics names Liisa Bayko as CFO

Mon, 20 Jul 2026 08:00:50 -0400

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has appointed Liisa Bayko as Chief Financial Officer, according to a statement from the clinical-stage biopharmaceutical company.

Bayko holds a B.S.

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer